Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

0.7090 -0.0210 (-2.88%)
Streaming Delayed Price Updated: 9:39 AM EDT, Jun 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,257
Open 0.7300
Bid (Size) 0.7000 (14)
Ask (Size) 0.7089 (1)
Prev. Close 0.7300
Today's Range 0.6919 - 0.7300
52wk Range 0.6500 - 6.400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
63 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-83.36%
-83.36%
1 Month
-28.67%
-28.67%
3 Month
-73.74%
-73.74%
6 Month
-81.91%
-81.91%
1 Year
-82.71%
-82.71%

More News

Read More
Aquestive Therapeutics Reveals Favorable Data From Epinephrine Trial For Allergies
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Earnings Outlook For Aquestive Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
Via Benzinga
Looking Into Aquestive Therapeutics's Return On Capital Employed
Via Benzinga
NASDAQ:AQST Shareholder Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
Via SBWire
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Via Benzinga
Earnings Scheduled For March 8, 2022
Via Benzinga
A Preview Of Aquestive Therapeutics's Earnings
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Via Benzinga
Week In Review: Adagene Forms $2.5 Billion, Four-Drug Partnership With Sanofi
Via Talk Markets
Aquestive Highlights Early Data From Allergy Treatment Candidate AQST-109 Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Via Benzinga
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shareholder Notice: Update in Lawsuit
Via SBWire
55 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.